Opens in a new tab or window A study presented at the American Society of Hematology annual meeting identified TCL1A as a potential predictive biomarker for blinatumomab (Blincyto) response in ...

Following is a transcript of her remarks: ECOG-ACRIN E1910 is a [study] that we recently published that looked at the role of blinatumomab in consolidation therapy in adults in newly diagnosed ALL.

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell ...

The association has set a fundraising target of RM1.8 million, aimed at providing vital treatments, including the possibility ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) ...

Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

The breakthrough, described in a New England Journal of Medicine paper and presented at a conference in mid-December, is called blinatumomab, an immunotherapy drug delivered to patients over a 28 ...

Next, he turns to a study of blinatumomab (BLIN) in pediatric ALL, which was presented during the ASH plenary session. BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL ...